19P - Durable Remissions Associated with anti-CTLA-4 and anti-PD1 Checkpoint Inhibitors in a Single Center (19P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Psychosocial Aspects of Cancer
Palliative and Supportive Care
Presenter Teresa Smit
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors T. Smit1, B.L. Rapoport2, R.I. Van Eeden2
  • 1Pharmacy, The Medical Oncology Centre of Rosebank, 2196 - Johannesburg/ZA
  • 2Medical Oncology, The Medical Oncology Centre of Rosebank, 2196 - Johannesburg/ZA

Abstract

Background

Treatment with the checkpoint inhibitors ipilimumab (IPI) and nivolumab (NIVO) are associated with durable remissions in patients (pts) with solid tumors. We describe the durable remissions associated with these agents. There were 19 pts treated with IPI and 25 pts treated with NIVO and 1 pt was treated with a combination of IPI and NIVO.

Methods

The purpose of this analysis is to describe the durable remissions associated with IPI and NIVO on a variety of solid tumors treated at a single centre. This is a retrospective data analysis from 45 pts treated either in an expanded access program, clinical trial setting or post-registration protocol.

Results

A total of 45 pts (30 males, 15 females) were analyzed. Three pts with metastatic malignant melanoma (MMM), 18 with non-small cell lung cancer (NSCLC), 2 with renal cell carcinoma (RCC) and 2 with Hodgkin’s disease (HD) were treated with NIVO and 19 with MMM received IPI. One NSCLC pt received a combination of IPI and NIVO (1 cycle). In total 167 cycles of NIVO (median = 4, range 1-16), and 64 cycles of IPI (median = 4 cycles, range 1-4) were administered. In the MMM group, there were 5 responses out 20 pts (25%) treated with IPI including 3 pts with durable complete response (CR) of 74+, 46+ and 34+ months. One MMM pt treated with NIVO has an ongoing partial response (PR) of 23 months. Among the pts with NSCLC 6 responses were documented among the 18 pts treated with NIVO (33%). Two of these pts had very good and durable PRs of 10+ and 18+ months. One RCC pt treated with NIVO has an ongoing PR of 13+ months. Two heavily pretreated pts with HD treated with NIVO have very good PRs of 14+ and 13+ months. Additionally, a very PR was documented in the NSCLC pt treated with the combination IPI and NIVO.

Conclusions

Anti-PD1 and anti-CTLA4 antibody treatment are associated with durable remissions in pts with a variety of solid tumours. Among our pts durable remissions and durable responses were documented in pretreated pts with RCC, NSCLC, HD and MMM.

Clinical trial identification

Legal entity responsible for the study

Prof Bernardo L. Rapoport

Funding

None

Disclosure

B.L. Rapoport: MSD: Adboards, Speaker engagements, Consultancy, Contract Research; BMS: Adboards, Speaker engagements, Consultancy, Contract Research, Research grant. All other authors have declared no conflicts of interest.